<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897412</url>
  </required_header>
  <id_info>
    <org_study_id>CBL-0202(Stage 2)</org_study_id>
    <nct_id>NCT04897412</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)</brief_title>
  <official_title>A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caliway Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caliway Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled,&#xD;
      parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of&#xD;
      CBL-514.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of abdominal subcutaneous fat volume</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat volume as measured by ultrasound around the treated area compared with placebo group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of abdominal subcutaneous fat thickness</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat thickness as measured by ultrasound around the treated area compared with placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of abdominal subcutaneous fat volume compare with baseline</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat volume as measured by ultrasound around the treated area compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of abdominal subcutaneous fat thickness compare with baseline</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat volume as measured by ultrasound around the treated area compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Number of participants experiencing TEAEs and number of individual TEAEs among treatment groups by severity and relationship to investigational product (IP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in physical examination</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Physical examinations include assessment of cardiovascular, respiratory, gastrointestinal, and neurological systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with injection site reactions</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Injection site reactions include but not limited to redness, swelling, bruising, tenderness, itching, pain, warmth, discoloration and hardness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Up to 4 weeks after last treatment</time_frame>
    <description>Clinical laboratory tests include Biochemistry, Hematology, Coagulation and Urinalysis test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in vital signs</measure>
    <time_frame>Up to 4 weeks after last treatment</time_frame>
    <description>Vital signs measurements include temperature, pulse rate, blood pressure, and respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in Electrocardiogram (ECG)</measure>
    <time_frame>Up to 4 weeks after last treatment</time_frame>
    <description>ECG parameters include heart rate, RR interval, PR interval, QT interval, QTc interval, and QRS interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction score compared with placebo group</measure>
    <time_frame>The 4th weeks after last treatment</time_frame>
    <description>Subject Satisfaction assessed by the 9-point CBL-514 Satisfaction Questionnaire (Satisfaction Questionnaire) score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Subcutaneous Fat</condition>
  <arm_group>
    <arm_group_label>CBL-514</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: 0.9% Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBL-514</intervention_name>
    <description>CBL-514 will be administered via injection into the abdominal subcutaneous adipose layer.</description>
    <arm_group_label>CBL-514</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride (0.9% NaCl) will be administered via injection into the abdominal subcutaneous adipose layer.</description>
    <arm_group_label>Placebo: 0.9% Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18 years to 64 years old (at Screening), inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) &gt; 18.5 and &lt; 35 kg/m2 and body weight ≥ 50 kg at Screening and&#xD;
             Day 1.&#xD;
&#xD;
          3. Subject has sufficient abdominal subcutaneous fat thickness of at least 2.00 cm (20.0&#xD;
             mm) and up to 5.00 cm (50.0 mm) measured by ultrasound, surrounding the center of&#xD;
             localized area of treatment at Screening and Day 1.&#xD;
&#xD;
          4. Subject has stable body weight (identified as ≦ 5% weight change per subject report)&#xD;
             for at least 3 months before Screening and during the study.&#xD;
&#xD;
          5. Subject who has maintained a stable lifestyle (e.g. exercise, eating patterns, and&#xD;
             smoking habit) per subject report for at least 3 months before Screening and during&#xD;
             the study.&#xD;
&#xD;
          6. Voluntarily signs the Informed Consent Form (ICF) and, in the opinion of the&#xD;
             Investigator or delegate, is physically and mentally capable of participating in the&#xD;
             study, and willing to adhere to study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subject of childbearing potential who is not willing to commit to an acceptable&#xD;
             contraceptive regimen with her partner from the time of Screening and throughout study&#xD;
             participation until 90 days after the last IP dose, or who is currently pregnant or&#xD;
             lactating. Male subject who is not willing to commit to an acceptable contraceptive&#xD;
             method.&#xD;
&#xD;
             Females who have been surgically sterilized (hysterectomy or bilateral oophorectomy)&#xD;
             or who are post-menopausal (defined as at least 50 years with ≥ 12 months of&#xD;
             amenorrhea with a follicle stimulating hormone (FSH) &gt; 40 IU/L are considered to be of&#xD;
             non-childbearing potential. Subjects who are not of childbearing potential are not&#xD;
             required to use contraception.&#xD;
&#xD;
          2. Subject diagnosed with coagulation disorders or is receiving&#xD;
             anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede&#xD;
             coagulation or platelet aggregation.&#xD;
&#xD;
          3. Subject has hemoglobin A1c (HbA1c) ≥ 9%, delayed wound healing, or any diabetic risks&#xD;
             which, in the opinion of Investigator, is inappropriate to participate in the study.&#xD;
&#xD;
          4. Subject has a clinically significant cardiovascular disease and abnormal findings in&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          5. Subject with active or prior history of malignancies within 5 years before Screening&#xD;
             or being worked-up for a possible malignancy. Except adequately treated basal cell&#xD;
             carcinoma of skin and in situ squamous cell carcinoma of skin would be eligible as per&#xD;
             Investigator's discretion.&#xD;
&#xD;
          6. Subject with a history of human immunodeficiency virus (HIV)-1, infection or subjects&#xD;
             with active HIV infection at Screening with positive HIV antigen/antibody (Ag/Ab)&#xD;
             combo test.&#xD;
&#xD;
          7. Subjects with any hepatic medical condition that would interfere with assessment of&#xD;
             safety or efficacy or compromise the subject's ability to undergo study procedures or&#xD;
             provide informed consent.&#xD;
&#xD;
          8. Subject has abnormal skin or local skin conditions at the treatment area, which in the&#xD;
             opinion of Investigator, is inappropriate to participate in the study, including but&#xD;
             not limited to any of the following:&#xD;
&#xD;
               1. Skin manifestations of a systemic disease,&#xD;
&#xD;
               2. Any abnormality of the skin or soft tissues of the area to be treated,&#xD;
&#xD;
               3. Grade III cellulite (Nürnberger and Muller scale, Nürnberger F, 1978) at the area&#xD;
                  to be treated,&#xD;
&#xD;
               4. Skin folding on treatment area when the subject is in the supine position,&#xD;
&#xD;
               5. Sensory loss or dysesthesia in the area to be treated,&#xD;
&#xD;
               6. Evidence of any cause of enlargement in the area to be treated other than&#xD;
                  localized abdominal or thigh subcutaneous fat,&#xD;
&#xD;
               7. Tattoos on the area to be treated.&#xD;
&#xD;
          9. Subject who has undergone the following procedures:&#xD;
&#xD;
               1. Previous surgery in the anticipated treatment area,&#xD;
&#xD;
               2. Metal implants of any type in the area to be treated,&#xD;
&#xD;
               3. Esthetic procedure i.e. liposuction to the region to be treated,&#xD;
&#xD;
               4. Esthetic procedure e.g. cryolipolysis, ultrasonic lipolysis, low level laser&#xD;
                  therapy (LLLT), lipolysis injection to the region to be treated within 12 months&#xD;
                  before Screening or during the study.&#xD;
&#xD;
         10. Subject is on prescription or OTC weight reduction medication or weight reduction&#xD;
             programs within 3 months before Screening or during the study.&#xD;
&#xD;
         11. Subject is undergoing chronic steroid or immunosuppressive therapy.&#xD;
&#xD;
         12. Requiring continual use of the following therapeutic agents during the study:&#xD;
             terfenadine (Teldane), buspirone (Buspar), fexofenadine (Fexotabs, Tefodine, Telfast,&#xD;
             Xergic, Allegra, etc.), any medication that is known to strongly inhibit or induce CYP&#xD;
             enzymes (please refer to Section 24.1), sensitive CYP substrates or drugs with narrow&#xD;
             therapeutic index, in the opinion of the investigator, may affect the evaluation of&#xD;
             the study product or place the participant at undue risk.&#xD;
&#xD;
             If a subject needs to use the above mentioned therapeutic agents during the study for&#xD;
             any reason, these therapeutic agents should not be used at least for 2 days prior to&#xD;
             dosing and until 1 day post-dose.&#xD;
&#xD;
         13. Unable to receive topical anesthesia (e.g., history of hypersensitivity to lidocaine).&#xD;
&#xD;
         14. Subjects with known allergies or sensitivities to the IP or its components.&#xD;
&#xD;
         15. Subjects with liver cirrhosis or with inadequate liver function at Screening defined&#xD;
             as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline&#xD;
             phosphatase (ALKP), total bilirubin (TBIL), or gamma-glutamyl transferase (GGT) &gt; 3.0&#xD;
             × upper limit of normal (ULN).&#xD;
&#xD;
         16. Subjects with any renal impairment, defined as abnormal serum creatinine, and urea &gt;&#xD;
             1.5 × ULN or estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73 m2. Subjects&#xD;
             who are currently on dialysis should be excluded.&#xD;
&#xD;
         17. Use of other investigational drug or device within 4 weeks prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Sheu</last_name>
    <phone>+886-2-26971355</phone>
    <phone_ext>1312</phone_ext>
    <email>CR@caliway.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site 3</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site 2</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site 4</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site 1</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site 5</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

